Piramal Pharma Limited — research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Piramal Pharma Limited, explained in plain English.

• ▪Piramal Pharma Limited is tracked in the Pharma & Healthcare sector of our NSE large-cap universe.
• ▪Reported fundamentals show a net margin of -3.41%, debt to equity of 69.98.
• ▪Our transparent MaxGrade checklist scores it D (36/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
• ▪Annualised volatility over the past year is 33.66% with a maximum drawdown of -34.71% and a beta of 1.16 against NIFTY 50.

Figures from the current session. Market open.